Inovio Pharmaceuticals (INO) Stock Price, News & Analysis

Company Overview

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Key Stats

• Today's Range: $2.17 to $2.25
• 50-Day Range: $1.78 to $2.32
• 52-Week Range: $1.74 to $14.75
• Volume: 165,032 shs
• Average Volume: 942,030 shs
• Market Capitalization: $57.34 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.40
• Consensus Rating: Moderate Buy

Inovio Pharmaceuticals Stock Analysis - MarketRank™

Inovio Pharmaceuticals scored higher than 66% of companies evaluated by MarketBeat, and ranked 309th out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Inovio Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Inovio Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Inovio Pharmaceuticals are expected to grow in the coming year, from ($4.23) to ($2.85) per share.

Price to Book Value per Share Ratio

Inovio Pharmaceuticals has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.99% of the float of Inovio Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Inovio Pharmaceuticals has a short interest ratio ("days to cover") of 5.1.

Change versus previous month

Short interest in Inovio Pharmaceuticals has recently increased by 2.45%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Inovio Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Inovio Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.3 / 5
• Environmental Score: -1.01

Percentage of Shares Shorted

13.99% of the float of Inovio Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Inovio Pharmaceuticals has a short interest ratio ("days to cover") of 5.1.

Change versus previous month

Short interest in Inovio Pharmaceuticals has recently increased by 2.45%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Inovio Pharmaceuticals this week, compared to 3 articles on an average week.

Search Interest

Only 5 people have searched for INO on MarketBeat in the last 30 days. This is a decrease of -64% compared to the previous 30 days.

MarketBeat Follows

Only 5 people have added Inovio Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -29% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Inovio Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.50% of the stock of Inovio Pharmaceuticals is held by insiders.

Percentage Held by Institutions

Only 26.79% of the stock of Inovio Pharmaceuticals is held by institutions.

INO Stock Analysis - Frequently Asked Questions

How have INO shares performed this year?

Inovio Pharmaceuticals' stock was trading at $1.83 at the start of the year. Since then, INO shares have increased by 21.3% and is now trading at $2.22.
View the best growth stocks for 2025 here.

How were Inovio Pharmaceuticals' earnings last quarter?

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) issued its quarterly earnings data on Thursday, August, 8th. The biopharmaceutical company reported ($1.19) earnings per share for the quarter, missing the consensus estimate of ($1.10) by $0.09. The biopharmaceutical company had revenue of $0.10 million for the quarter, compared to the consensus estimate of $0.10 million.

When did Inovio Pharmaceuticals' stock split?

Inovio Pharmaceuticals's stock reverse split on the morning of Thursday, January 25th 2024. The 1-12 reverse split was announced on Thursday, January 25th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 25th 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

Who are Inovio Pharmaceuticals' major shareholders?

Top institutional shareholders of Inovio Pharmaceuticals include Deep Track Capital LP (11.95%), Stonepine Capital Management LLC (4.02%), AIGH Capital Management LLC (2.51%) and Bank of America Corp DE (2.46%). Insiders that own company stock include David B Weiner and Simon X Benito.
View institutional ownership trends.

How do I buy shares of Inovio Pharmaceuticals?

Shares of INO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Inovio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Inovio Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Moderna (MRNA), Novavax (NVAX) and Pfizer (PFE).

Company Calendar

• Last Earnings: 8/08/2024
• Today: 2/20/2025
• Next Earnings (Estimated): 3/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:INO
• CUSIP: N/A
• CIK: 1055726
• Web: www.inovio.com
• Phone: (267) 440-4200
• Fax: 267-440-4242
• Employees: 320
• Year Founded: 1979

Price Target and Rating

• Average Stock Price Target: $12.40
• High Stock Price Target: $20.00
• Low Stock Price Target: $3.00
• Potential Upside/Downside: +458.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-135,120,000.00
• Net Margins: N/A
• Pretax Margin: -55,315.44%
• Return on Equity: -118.17%
• Return on Assets: -83.47%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.88
• Quick Ratio: 3.88

Sales & Book Value

• Annual Sales: $830,000.00
• Price / Sales: 69.81
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.16 per share
• Price / Book: 0.43

Miscellaneous

• Outstanding Shares: 26,100,000
• Free Float: 25,448,000
• Market Cap: $57.94 million
• Optionable: Optionable
• Beta: 0.89